Drug Trial Radar · NCT07020949
Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM
Last checked: Nov 19, 2026Latest source record: Jun 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Jun 13, 2024
Primary completion
Nov 27, 2024
Study completion Nov 27, 2024
Sponsor
- Lead sponsor
- Tonghua Dongbao Pharmaceutical Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics, and efficacy of THDBH120 injection in participants with T2DM. This study includes three multiple-ascending dose cohorts.
Conditions
- Diabetes Mellitus Type 2
Interventions
THDBH120 injectionDrug
Participants received THDBH120 by subcutaneous injection.
Placebo of THDBH120 injectionDrug
Participants received placebo by subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s)Time frame: 78 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.